Trevi Therapeutics Q3 EPS $(0.13), Inline
Benzinga Newsdesk 2 hours ago
NewsEarnings
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.